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ABSTRACT 
Background: Transcatheter uterine artery embolisation (UAE) for the treatment of symptomatic fibroids has been 
performed in several centres in the United States, Western Europe and Asia with promising results. This study reports 
the authors' experience with UAE at the University Malaya Medical Centre. Method: Fifty women with symptomatic 
uterine  fibroids  who  declined  surgery  were  treated  by  transcatheter  UAE.  The  uterine  arteries  were  selectively 
catheterised and embolised with polyvinyl alcohol particles. Post-procedure analgesia was administered via patient-
controlled analgesic pump. The patients were followed up at an interval of 6/12 clinically and with MRI. Results: 
Transcatheter UAE was performed on all 50 patients with no major complications. 49 patients had both uterine arteries 
embolised while 1 patient had only the right uterine artery embolised on account of hypoplasia of the left uterine artery 
due to previous myomectomy. The mean hospital stay was 3.5 days (range, 2 to 7). At a mean follow-up of 24/52, all 
patients reported improvements in their presenting symptoms. Objective improvement in terms of reduction of uterine 
and fibroid sizes was determined on MRI. One patient, who initially responded with a decrease in uterine and dominant 
fibroid size, became symptomatic (menorrhagia) after 6 months and subsequent endometrial sampling revealed cystic 
glandular hyperplasia for which total abdominal hysterectomy was performed. Two other patients had no change in 
symptoms and after hysterectomy, the pathology revealed concurrent adenomyosis. Another 2 patients with cervical 
fibroids were treated with hysterectomy as there was no gross reduction in the size of fibroid following UAE. Overall, 
90% of the patients had dramatic improvement of anaemia and symptoms at 1 year follow-up. Conclusion: Out of the 
50 patients, 17 patients had total disappearance of their fibroids and 28 patients had more than 50% reduction in the size 
of fibroids after 1 year. 5 patients ended up with total abdominal hysterectomy. These results suggest that UAE is an 
appealing alternative to hysterectomy or myomectomy for many women with symptomatic fibroids. © 2010 Biomedical 
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INTRODUCTION 
The  most  common  tumour  in  women  of  the 
reproductive  age  group  are  uterine  fibroids.  They  are 
symptomatic  in  about  50%  of  women  and  produce  a 
variety of symptoms. These symptoms include menstrual 
disturbances,  pelvic  pain,  pressure  symptoms  and 
compromised  reproductive  function  [1].  The  standard 
therapy  for  fibroids  has  been  surgical  removal  by 
hysterectomy or myomectomy, if medical therapy fails.  
In  1995,  Ravina  et  al.  introduced  the  use  of 
transcatheter uterine artery embolisation. (UAE) as the 
primary treatment of uterine fibroids with encouraging 
results  [2].  Since  then,  it  has  gained  popularity  as  a 
minimally  invasive,  uterine-sparing  procedure  and 
currently  more  than  100,000  procedures  have  been 
performed worldwide [3,4]. UAE is not a new vascular 
intervention  technique  as  it  has  been  recognised  as  a 
superior  first-line  alternative  to  surgery  for  control  of 
obstetric  haemorrhage  since  the  1990s  [5].  The 
utilisation of UAE for the primary treatment of fibroids 
is,  however,  a  more  recent  phenomenon.  This  study 
reports  preliminary  experience  with  UAE  in  the  local 
population  as  this  has  never  been  done  before  in  this 
country.  
MATERIALS AND METHODS 
The  patients  were  recruited  from  the  gynaecology 
clinic  of  the  centre.  All  of  them  presented  with 
symptomatic fibroids, having declined, or been deemed 
medically unfit for surgery. Their symptoms were found 
to be due to fibroids and were of sufficient severity to 
warrant surgical management.  
The  patients  were  selected,  screened  and 
investigated  relevantly  in  the  Department  of 
Gynaecology  and  treated  in  collaboration  with  the 
Interventional  Radiologists.  All  patients  were  treated 
according to the protocol approved by the institution’s 
ethics  committee  and  with  informed  consent.  The 
inclusion  criteria  included  healthy  pre-menopausal 
women between the ages of 38 and 55 years, not desirous 
of pregnancy, with large uteri (>12 weeks’ size) due to 
fibroids, and with at least one of the following symptoms: 
i) anaemia, ii) menorrhagia, iii) dysmenorrhoea, and iv) 
mass per abdomen with pressure symptoms. Underlying 
gynaecological malignancy was excluded by endometrial 
sampling.  
The exclusion criteria included contraindications to 
Magnetic Resonance Imaging (MRI), severe allergy to 
iodinated contrast media, undiagnosed vaginal bleeding, 
subserosal  pedunculated  fibroids,  patients  on 
anticoagulation  therapy  or  having  clotting  disorders, 
infection,  immuno-compromised  patients  and  patients 
who had not completed their family. A history of current 
and previous medical therapy for fibroids was recorded. 
An ultrasound of the pelvis was initially performed at the 
Gynaecology  clinic  to  confirm  the  presence  of  uterine 
fibroids. An MRI using a 1.5 Tesla Siemens Magnetom 
Vision machine was subsequently carried out as a pre-
requisite to the procedure. The MRI protocol used was a 
T1-  and  T2-weighted  axial,  T2-weighted  sagittal  and 
post-contrast T1-weighted axial and sagittal images. The 
patients who presented with menorrhagia were analysed 
based  on  the  haemoglobin  levels  and  duration  of 
menorrhagia (use of sanitary napkins exceeding 12 per 
day).  
Pre-procedural blood tests included full blood count, 
coagulation profile, as well as creatinine and electrolyte 
levels.  All  the  selected  cases  were  discussed  with  the 
interventional radiologist. The patients were also referred 
to  the  Acute  Pain  Service  for  evaluation  by  an 
anaesthetist  and  instructed  on  the  use  of  patient-
controlled analgesia (PCA). 
The  procedure  was  performed  during  the  first 
10 days of the patient’s menstrual cycle, after carefully 
excluding pregnancy. A urine pregnancy test was carried 
out in all sexually active patients in the reproductive age 
group.  The  patient  was  admitted  a  day  before  the 
procedure and was required to fast for 6 hours prior to 
the procedure. Prophylactic broad-spectrum intravenous 
antibiotic (Cefuroxime) was administered an hour before 
the  procedure.  Intra-procedural  sedation  and  analgesia 
were  administered  by  the  attending  radiologist.  The 
standard protocol for analgesia was the administration of 
a bolus dose of 3 mg of morphine before the start of the 
procedure followed by 2 mg before embolisation of each 
side.  
The  right  common  femoral  artery  was  punctured 
using  a  one-part  needle  and  a  5F  Robert’s  uterine 
catheter  was  advanced  into  the  left  uterine  artery.  A 
diagnostic  contrast  run  was  done  to  evaluate  the 
vascularity  of  the  fibroid  and  to  identify  the  ovarian 
arteries.  The  tip  of  the  catheter  was  then  advanced 
beyond the origin of the ovarian artery. Subsequently the 
left uterine artery was embolised with polyvinyl alcohol 
(PVA)  particles  (300  to  500  microns  in  size).  The 
procedure was repeated on the right side. There were no 
microcatheters  used  in  all  our  patients.  A  post-
embolisation  run  was  done  prior  to  removal  of  the 
catheter.  
All patients were observed as in-patients for at least 
24  hours  after  the  procedure.  The  PCA  was  set  at 
morphine  1mg/bolus  with  a  5-minute  lockout  at  a 
maximum of 10mg/h. The amount of morphine required, 
length  of  hospital  stay  and  occurrence  of  any 
complication was noted. They were discharged with non-
steroidal  anti-inflammatory  drugs  (NSAIDs)  or 
mefenamic  acid  of  a  week's  duration.  After  discharge 
from the hospital, the patients were reviewed at 3, 6 and 
12 months respectively. The severity of the presenting 
symptoms  was  reassessed.  A  follow-up  MRI  was 
performed at 6 and 12 months.  
RESULTS 
Fifty  women  aged  between  38  and  52  years 
(mean, 43) were referred for UAE for the treatment of 
symptomatic  fibroids.  Menorrhagia  was  present  in RN Subramaniam et al. Biomed Imaging Interv J 2010; 6(3):e27    3 
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35 (70%) women, dysmenorrhoea in 12 (24%) women, 
pressure symptoms in 3 (6%) women, and anaemia in 
32 (64%)  women.  The  mean  haemoglobin  level  was 
9.9 mg/dL. The subjects had previously received medical 
treatment, namely hormonal therapy (progestogen) and 
NSAIDs.  Six  patients  had  undergone  previous 
myomectomy.  There  were  eight  women  with  chronic 
medical disorders such as diabetes mellitus, hypertension, 
bronchial  asthma,  thalassaemia  minor  and  idiopathic 
thrombocytopenic purpura (ITP).  
Forty percent of the women had received previous 
treatment  with  blood  transfusions,  oral  progestogens 
(NET),  gonadotropin  (zoladex)  and  previous 
myomectomy  (six  women).  Ninety  percent  of  the 
patients reported that menorrhagia had a heavy impact on 
their lifestyle in terms of interfererence with sleep, being 
housebound or having to be close to a washroom during 
menstruation. 
UAE  was  successfully  performed  on  all  patients. 
49 patients had both uterine arteries embolised; while 1 
patient  had  only  the  right  uterine  artery  embolised  on 
account of hypoplasia of the left uterine artery.  
The mean procedure time was 60 min (range, 30 to 
90).  There  were  no  complications  associated  with  the 
procedure  itself  (contrast  media,  groin  haematomas). 
Nine  patients  developed  fever  and  four  developed 
urinary  tract  infection.  Two  of  the  patients  developed 
blood-stained  discharge  for  about  a  week  after  the 
procedure.  Post-procedural  pain  was  well-controlled  in 
all  women.  The  mean  hospital  stay  was  3.5  days 
(range, 2 to 7). All patients were followed up at 3, 6 and 
12 months. 90% of the patients reported improvement in 
the  presenting  symptoms.  On  follow-up  at  the  clinic, 
they  were  questioned  regarding  their  menstrual  cycle, 
change  in  lifestyle  and  overall  well-being.  A  standard 
quality-of-life  score  was  not  utilised.  Objective 
improvement, in terms of reduction of uterine and fibroid 
sizes,  was  determined  by  MRI.  There  was  more  than 
50%  reduction  in  the  size  of  the  fibroid  in  28  (56%) 
patients and total disappearance of the fibroid in 17 (34%) 
participants. Uterine and fibroid volumes were calculated 
based  on  MRI  including  maximum  diameters  in  three 
planes  (longitudinal  [D1],  anterior  posterior  [D2],  and 
transverse [D3]). Measurements were only taken of the 
dominant or largest fibroid. Uterine and fibroid volumes 
were calculated using the formula V=0.5233xD1xD2xD3. 
The number and location of fibroids were also recorded. 
Majority of the women who participated in this study had 
single  fibroid  (39  women)  and  about  11  women  had 
more  than  5  fibroids.  Pre-embolisation  uterine  volume 
was about 520 cm
3.  
Five  patients  had  total  abdominal  hysterectomy 
following  UAE.  Two  patients  had  concurrent 
adenomyosis, one had persistent menorrhagia with cystic 
glandular  hyperplasia  and  two  patients  with  cervical 
fibroid showed no reduction in the size with persistence 
of  pressure  symptoms.  Two  women,  aged  47  and 
52 years,  experienced  transient  amenorrhoea  at  12  and 
24 weeks,  respectively,  after  UAE,  but  did  not  have 
symptoms  associated  with  menopause.  The  transient 
amenorrhoea  in  both  these  patients  lasted  for  about 
9 months and they had resumed their normal menstrual 
cycle at the one-year follow-up. 
DISCUSSION 
Uterine leiomyomata is a major health problem that 
afflicts  at  least  about  20-40%  of  women  in  the 
reproductive age group worldwide. The symptoms vary 
from abnormal bleeding to pain and pressure symptoms 
[3]. The true prevalence of fibroids is relatively unknown 
as they are only symptomatic in about 50% of women 
who develop them [6]. About 20-30% of hysterectomies 
are performed as a treatment for uterine fibroids. Another 
alternative treatment option is the use of gonadotrophin-
releasing  hormone  agonists,  either  alone  or  in 
combination  with  conservative  surgical  treatments  like 
myomectomy [7]. However, studies show that there is a 
significant rate (20-30%) of recurrence in fibroids after a 
myomectomy [8]. In fact, in this series, 6 women had 
previous  myomectomy  with  recurrence  of  fibroids  and 
symptoms.  
Over  the  past  decade,  uterine  artery  embolisation 
(UAE) has been described as an alternative to invasive 
surgical  procedures.  Many  studies  have  addressed  this 
treatment  option  over  the  past  10  years.  UAE  is  a 
percutaneous,  image-guided  procedure  which  is 
performed  by  a  trained  interventional  radiologist.  It 
involves  the  placement  of  a  catheter  into  the  uterine 
arteries  via  a  common  femoral  artery  approach  and 
injection of embolic material (polyvinyl alcohol particles 
or  gelfoam)  into  both  uterine  arteries  until  the  flow 
becomes  sluggish  [2,  9-12].  The  mechanism by  which 
 
Table 1  The outcome at 6 months clinical follow-up 
Symptoms at 6 Month Follow-up  No. of Patients 
Scanty Menses  19 
Normal Menses  24 
Transient Amenorrhea  2 
Persistent Menorrhagia  5 RN Subramaniam et al. Biomed Imaging Interv J 2010; 6(3):e27    4 
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UAE acts is by reducing blood flow to the fibroid thus 
inducing irreversible ischaemia which leads to necrosis 
and  shrinkage.  The  normal  myometrium,  however, 
recovers well from this ischaemic event [12].  
The  procedure  generally  takes  about  an  hour. 
Immediately  after  the  procedure,  most  patients 
experience cramping pain. This ischaemic pain generally 
lasts  for  8-12  hours  post-procedure  [12].  Patients  are 
usually  kept  overnight  for  pain  management.  In  this 
centre,  patients  are  instructed  on  the  use  of  Patient 
Controlled  Analgesia  which  is  administered  by  an 
anaesthetist. The study also follows a protocol of 3 mg of 
morphine i/v before the start of the procedure and 2 mg 
before embolisation of each side. This protocol has been 
tolerated well by the patients in this series and they have 
been  pain-free  during  the  first  24  hours.  They  are 
discharged home with oral anaelgesics and do not report 
any pain-related complications on follow-up. 
Another  issue  to  consider  is  that  of  fertility.  The 
effect of UAE on subsequent fertility and pregnancy has 
been understudied and therefore it is not recommended 
in women desirous of future pregnancies [13]. Transient 
 
Figure 1  Prevalence of symptoms: 70% of the patients presented with menorrhagia, 24% presented with pain and 




Figure 2  This  figure  shows  the  outcome  of  the  50  patients  at  1-year  follow  up.  56%  of  patients  had  50% 
reduction of volume as measured on MRI. 34% of the patients had complete absence of the fibroid and 
10% had hysterectomy done. RN Subramaniam et al. Biomed Imaging Interv J 2010; 6(3):e27    5 
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or  permanent  amenorrhea,  with  symptoms  of  ovarian 
failure, have been reported in about 5% of patients after 
UAE. This has been attributed to ovarian embolisation 
via collaterals resulting in ovarian ischaemia [14]. Due to 
this concern, many studies were carried out to evaluate 
ovarian reserve by measuring the FSH levels before and 
after UAE. It was reassuring that there was no change 
detected  in  the  ovarian  reserve,  but  long-term  studies 
have  been  recommended  to  further  address  this  issue 
[15]. In this study, all patients who had not completed 
their family were excluded. 
There are some limitations in this study that have to 
be addressed. Firstly, the follow-up period of 1 year is 
too short. Most of the patients did not return for a follow-
up after the 1-year period and there is no data regarding 
their  long-term  clinical  outcome.  According  to 
Hehenkamp et al. (2008), about 25% of patients in the 
EMMY trial had secondary hysterectomy after UAE at 
24 months [16]. Currently, there are only 7 patients, out 
of the 50 in this series, who are still on regular follow-up 
and are doing well. Secondly, this study did not use a 
standard quality-of-life (QOL) questionnaire on follow-
up. The patients were asked about their symptoms based 
on their menstrual cycle history. The authors recommend 
that a standard QOL score be done for further studies in 
the future.  
CONCLUSION 
The mid-term results of UAE for the treatment of 
symptomatic fibroids in our hospital indicate this to be a 
safe and effective therapeutic option. A longer period of 
follow-up  with  a  greater  number  of  patients  in  this 
ongoing study will be needed to confirm that UAE is a 
viable option, acceptable to both patients and clinicians. 
This study illustrates that large numbers of women with 
symptomatic fibroid disease are averse to surgery despite 
their  burden  of  suffering,  and  are  actively  seeking 
alternatives  to  hysterectomy.  UAE  is  a  nonsurgical 
option for management of fibroid related symptoms that 
has  shown  excellent  technical  and  clinical  success. 
Although  there  have  been  many  similar  studies  done 
globally over the past 10 years, there has not been any 
published South-East Asian series and the authors feel 
that  this  preliminary  experience  would  be  helpful  to 
clinicians in this region. 
REFERENCES 
1.  Lumsden  MA,  Wallace  EM.  Clinical  presentation  of  uterine 
fibroids. Baillieres Clin Obstet Gynaecol. 1998;12(2):177-95. 
2.  Ravina  JH,  Herbreteau  D,  Ciraru-Vigneron  N,  et  al.  Arterial 
embolisation  to  treat  uterine  myomata.  Lancet. 
1995;346(8976):671-2. 
3.  Goodwin  SC,  Spies  JB,  Worthington-Kirsch  R,  et  al.  Uterine 
artery  embolization  for  treatment  of  leiomyomata:  long-term 
outcomes  from  the  FIBROID  Registry.  Obstet  Gynecol. 
2008;111(1):22-33. 
4.  Edwards  RD,  Moss  JG,  Lumsden  MA,  et  al.  Uterine-artery 
embolization versus surgery for symptomatic uterine fibroids. N 
Engl J Med. 2007;356(4):360-70. 
5.  Hansch  E,  Chitkara  U,  McAlpine  J,  et  al.  Pelvic  arterial 
embolization  for  control  of  obstetric  hemorrhage:  a  five-year 
experience. Am J Obstet Gynecol. 1999;180(6 Pt 1):1454-60. 
6.  Greenberg MD, Kazamel TI. Medical and socioeconomic impact 
of  uterine  fibroids.  Obstet  Gynecol  Clin  North  Am. 
1995;22(4):625-36. 
7.  Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery 
embolization  versus  abdominal  hysterectomy  for  treatment--a 
prospective, randomized, and controlled clinical trial. Radiology. 
2003;226(2):425-31. 
8.  Rossetti  A,  Sizzi  O,  Soranna  L,  et  al.  Long-term  results  of 
laparoscopic  myomectomy:  recurrence  rate  in  comparison  with 
abdominal myomectomy. Hum Reprod. 2001;16(4):770-4. 
9.  Walker  WJ,  Pelage  JP.  Uterine  artery  embolisation  for 
symptomatic fibroids: clinical results in 400 women with imaging 
follow up. BJOG. 2002;109(11):1262-72. 
10.  Spies  JB,  Scialli AR,  Jha  RC, et al.  Initial  results from uterine 
fibroid embolization for symptomatic leiomyomata. J Vasc Interv 
Radiol. 1999;10(9):1149-57. 
11.  Pelage JP, Le Dref O, Soyer P, et al. Fibroid-related menorrhagia: 
treatment with superselective embolization of the uterine arteries 
and midterm follow-up. Radiology. 2000;215(2):428-31. 
12.  Tropeano G, Amoroso S, Scambia G. Non-surgical management of 
uterine fibroids. Hum Reprod Update. 2008;14(3):259-74. 
13.  Hovsepian DM, Siskin GP, Bonn J, et al. Quality improvement 
guidelines  for  uterine  artery  embolization  for  symptomatic 
leiomyomata. J Vasc Interv Radiol. 2004;15(6):535-41. 
14.  Spies JB, Ascher SA, Roth AR, et al. Uterine artery embolization 
for leiomyomata. J Obstet Gynaecol. 2001;21(Supplement 1):29-
37. 
15.  Ahmad A, Qadan L, Hassan N, et al. Uterine artery embolization 
treatment of uterine fibroids: effect on ovarian function in younger 
women. J Vasc Interv Radiol. 2002;13(10):1017-20. 
16.  Hehenkamp WJ, Volkers NA, Birnie E, et al. Symptomatic uterine 
fibroids:  treatment  with  uterine  artery  embolization  or 
hysterectomy--results from the randomized clinical Embolisation 
versus Hysterectomy (EMMY) Trial. Radiology. 2008;246(3):823-
32.RN Subramaniam et al. Biomed Imaging Interv J 2010; 6(3):e27    6 
    This page number is not 
    for citation purposes 
 
 
   
(a)  (b) 
Figure 3  (a) The initial contrast run into the right uterine artery. The tortuous and enlarged right uterine artery 
and the rich blood supply to the fibroid can be seen; (b) the post-embolisation contrast run which shows 
staining of the fibroid and no opacification of the arteries seen in the previous run. 
   
(a)  (b) 
Figure 4  A 50-year-old woman presented with menorrhagia for the past three months. An initial MRI (a) showed 
the presence of an anterior intramural fibroid. She underwent a UAE and a follow-up MRI at 1 year (b) 
showed complete absence of the fibroid. 
   
(a)  (b) 
Figure 5  A 45-year-old woman presented with a two-month history of menorrhagia which required repeated 
blood  transfusion.  She  was  advised  to  have  surgery  but  declined.  Her  initial  MRI  (a)  showed  the 
presence of a large submucosal fibroid. Due to her clinical status, a decision was taken to do a UAE. 
Her follow-up MRI at 1 year (b) shows complete absence of the fibroid. 